V92™ Cellular Bone Matrix Launches

January 11, 2016by Laura Brinker
V92™ Cellular Bone Matrix

Paragon 28® is pleased to announce the launch of the V92 Cellular Bone Matrix.  V92 is a viable allogeneic bone scaffold derived from bone marrow, in full compliance with FDA guidelines regarding human cells, tissues and cellular tissue-based products, and is intended for homologous use as a bone void filler.

Key Features

  • Two unique scaffold blends for optimal handling characteristics: V92™ and V92™-FC
  • Proprietary, optimized bone microparticulate size range of 100-300 μm.2
  • Novel DMSO-free cryoprotectant, with no rinsing and decanting steps required prior to use.
  • Average cell viability of the cell component exceeds 80% post-thaw.3
  • Minimum of 150,000 viable cells per cc of allograft post-thaw.3
  • Convenient handling and preparation in the OR, with total preparation time on the back table less than 20 minutes.
  • Four (4) hour working window for implantation after thaw without loss of cell viability.
  • Product shelf-life is two (2) years from date of processing when stored at -65°C or colder.
  1. Gruskin, E. et.al., Demineralized bone matrix in bone repair: history and use. Advanced Drug Delivery Reviews, 2012. 64:1063-1077.
  2. Malinin, T.I., et. al., Particulate bone allograft incorporation in regeneration of osseous defects; importance of particle sizes. The Open Orthopeadics Journal, 2007. 1:19-24.
  3. Data on file at Vivex Biomedical, Inc.

*Data on File – UMTB Biomedical


Paragon 28 Logo
14445 Grasslands Dr. Englewood, CO 80112

Follow us:


The name “Paragon 28” was chosen by design — to never lose focus on our goal to advance the science of foot and ankle surgery.

© 2024 Paragon 28, Inc.

Privacy Policy